Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab for Lung Cancer Prevention (CANAL)
NCT05725343Phase 3Terminated
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Feb 2022
- Primary completion
- Apr 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in lung cancer comparing Canakinumab with Placebo (2 arms). Primary endpoint: Time To Lung Cancer up to 48 months. Started Feb 2022; status: terminated.
02
Drugs
canakinumab
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT05725343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05725343.